Millions of people are turning to weight-loss medications in the hope of improving their health, reducing future risks, and gaining better control over their weight. But researchers are now investigating whether the benefits of these drugs could extend far beyond the number on the scale.
According to a new study from Houston Methodist Hospital, published in Annals of Oncology and reported by Medical News Today, GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound may be linked to a significantly lower risk of several obesity-related cancers.
A striking discovery
Researchers examined health records from more than 229,000 adults with obesity who did not have diabetes. They compared people prescribed GLP-1 medications with those who received standard diet and exercise counseling.
The findings showed that people taking semaglutide- or tirzepatide-based treatments had a 41% lower overall risk of developing cancers commonly associated with obesity.
Also read: What Happens When You Eat a Banana Before Sleep?
The strongest reductions were seen in endometrial cancer, colorectal cancer, pancreatic cancer, and multiple myeloma, where the risk was reduced by more than half.
More than weight loss?
Scientists believe the explanation may involve more than simply losing weight. While obesity is known to increase inflammation and metabolic dysfunction, GLP-1 drugs may also influence biological pathways connected to cancer development.
The medications have already been linked to improvements in cardiovascular health and insulin sensitivity, leading researchers to explore whether these broader effects could also play a role in lowering cancer risk.
As the use of GLP-1 treatments continues to surge worldwide, understanding their full impact on long-term health has become a growing area of scientific interest.
Also read: Study finds link between high BMI and 19 different types of cancer
Experts urge caution
Despite the promising results, specialists not involved in the study stress that the research does not prove the medications prevent cancer.
The study was observational, meaning it identified an association rather than a direct cause-and-effect relationship. Other factors, including lifestyle, diet, exercise habits, and healthcare access, may have influenced the results.
Researchers say larger and longer-term studies will be needed before GLP-1 medications can be considered a tool for cancer prevention. For now, the findings represent an intriguing development that could reshape future research into obesity and cancer.
Also read: Scientists uncover new link between stress, sleep and dementia
Also read: Millions of fans expected at the FIFA World Cup: Here are the biggest health risks